Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study
Endocrinology and Metabolism · 2025
DOI: 10.3803/enm.2024.2180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology and Metabolism, 2025. Verfasst von Shintaro Iwama und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Adrenocorticotropic Hormone, CTLA-4 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Anti-cytotoxic T-lymphocyte antigen-4 antibody (CTLA-4-Ab) monotherapy induces two types of pituitary immunerelated adverse events (irAEs): multiple pituitary hormone deficiency (Multi-D; impairment of ≥2 anterior pituitary hormones) and isolated adrenocorticotropic hormone (ACTH) deficiency (IAD). Combination therapy with CTLA-4-Ab and anti-programmed cell death-1 antibody (PD-1/CTLA-4-Abs), which is increasingly replacing CTLA-4-Ab monotherapy, frequently causes pituitary irAEs; however, whether it increases Multi-D/IAD incidence is unknown.
Methods
In total, 74 and 748 patients with malignancies treated with PD-1/CTLA-4-Abs and PD-1-Ab, respectively, were prospectively evaluated for ACTH and cortisol levels at baseline and every 6 weeks after treatment initiation, and then observed until the last clinical visit. The characteristics of pituitary irAEs were evaluated by pituitary stimulation tests and compared with those induced by PD-1-Ab monotherapy.
Results
PD-1/CTLA-4-Abs therapy showed higher incidence rates of pituitary irAEs (16/74 [21.6%] vs. 25/748 [3.3%], P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
- Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan.
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Iwama, S., Kobayashi, T., Izuchi, T., Suzuki, K., Murase, T., Ando, M., Handa, T., Onoue, T., Miyata, T., Sugiyama, M., Hagiwara, D., Suga, H., Banno, R., Hase, T., Mori, S., Sano, T., Akamatsu, S., Akiyama, M., Ishii, M., & Arima, H. (2025). Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study. Endocrinology and Metabolism. https://doi.org/10.3803/enm.2024.2180
Vancouver
Iwama S, Kobayashi T, Izuchi T, Suzuki K, Murase T, Ando M, et al. Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study. Endocrinology and Metabolism. 2025. doi:10.3803/enm.2024.2180
BibTeX
@article{Iwama2025,
author = {Iwama, Shintaro and Kobayashi, Tomoko and Izuchi, Tetsushi and Suzuki, Koji and Murase, Takanori and Ando, Masahiko and Handa, Tomoko and Onoue, Takeshi and Miyata, Takashi and Sugiyama, Mariko and Hagiwara, Daisuke and Suga, Hidetaka and Banno, Ryoichi and Hase, Tetsunari and Mori, Shoichiro and Sano, Tomoyasu and Akamatsu, Shusuke and Akiyama, Masashi and Ishii, Makoto and Arima, Hiroshi},
title = {Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study},
journal = {Endocrinology and Metabolism},
year = {2025},
doi = {10.3803/enm.2024.2180}
}
EUVIMED